(TheNewswire)
Vancouver, BC –
TheNewswire
–
March 29, 2023
–
Izotropic
Corporation
(“
Izotropic
” or the
“
Company
”) (CSE:
IZO
)
(OTC:
IZOZF
)
(FSE:
1R3
), a medical device company commercializing IzoView, a
dedicated breast CT (computed tomography) imaging platform, for the
more accurate detection and diagnosis of breast cancers, announces its
intent to extend unsecured loans.
On March 30, 2022, the Company entered into a
non-brokered private placement of unsecured promissory notes in which
the Company issued notes for $2,050,000.00 with the option for the
Company to acquire an additional $2,000,000.00 subject to terms to be
determined at a later date. A total of 826,613 detachable share
purchase warrants exercisable at $0.62 for a period of two years (yet
unexercised) were also issued.
Under the agreement notes mature one year from the date
of issuance and bear simple interest at 1% per month from the date of
issuance and payable every three months or, be subject to an original
issuance discount in lieu of paying interest. The final terms were to
be determined subject to the policies of the Canadian Securities
Exchange.
The Company now plans to extend the agreement and loan
period and is in discussions with the two lenders in this regard. The
intention is to repay the loans in cash and or equity in future and
the new terms will be announced when finalized.
ON BEHALF OF THE BOARD
Investor Relations Contact:
Email:
info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Ms. Jaclyn Thast
Email:
jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly traded
company commercializing a dedicated breast CT imaging platform,
IzoView, for the more accurate detection and diagnosis of breast
cancers. To expedite patient and provider access to IzoView,
Izotropic’s initial clinical study intends to demonstrate superior
performance of diagnostic breast CT imaging over diagnostic
mammography procedures. In follow-on clinical studies, Izotropic
intends to validate platform applications, including breast screening
in radiology, treatment planning and monitoring in surgical oncology,
and breast reconstruction and implant monitoring in plastic and
reconstructive surgery.
More information about Izotropic Corporation can be
found on its website at
izocorp.com
and by reviewing its profile on SEDAR at
sedar.com.
Forward-Looking Statements
This document may contain statements that are
“Forward-Looking Statements,” which are based upon the
current estimates, assumptions, projections, and expectations of the
Company’s management, business, and its knowledge of the relevant
market and economic environment in which it operates. The Company has
tried, where possible,
to identify such
information and statements by using words such as
“anticipate,” “believe,” “envision,”
“estimate,” “expect,” “intend,”
“may,” “plan,” “predict,”
“project,” “target,” “potential,”
“will,” “would,” “could,”
“should,” “continue,” “contemplate” and
other similar expressions and derivations thereof in connection with
any discussion of future events, trends or prospects or future
operating or financial performance, although not all forward-looking
statements contain these identifying words.
These statements are not guarantees of performance and
involve risks, including those related to capital requirements and
uncertainties that are difficult to control or predict, and as such,
they may cause future results of the Company’s activity to differ
significantly from the content and implications of such statements.
Forward-Looking Statements are pertinent only as of the date on which
they are made, and the Company undertakes no obligation to update or
revise any Forward-Looking Statements to reflect new information or
the occurrence of future events or circumstances unless otherwise
required to do so by law. Neither the Company nor its shareholders,
officers, and consultants shall be liable for any action and the
results of any action taken by any person based on the information
contained herein, including, without limitation the purchase or sale
of Company securities. Nothing in this document should be deemed to be
medical or other advice of any kind. All images are for illustrative
purposes only. IzoView is not yet approved for sale.
Copyright (c) 2023 TheNewswire – All rights reserved.
